Early this month, the FDA just approved a new drug for depression called esketamine. Esketamine, marketed under the brand name Spravato, is a ketamine-based drug designed for patients who aren’t responding to conventional antidepressant medications. It comes in a nasal spray form, and is touted to be the world’s first quick-relief depression medication in the market.
No comments:
Post a Comment